Polygenic scoring may alter breast cancer risk tiers in pathogenic variant carriers
The question at the center of this ESMO Open abstract is straightforward but clinically consequential: what happens to breast cancer risk stratification when a polygenic score is added to the assessment of women who already carry a pathogenic variant? In genetic counseling, a single high-penetrance variant often sets the frame for decision-making, but that frame can be too rigid for real-world risk prediction. A pathogenic variant identifies inherited susceptibility; it does not fully describe how that susceptibility will express itself across a lifetime.
That gap is where polygenic modeling enters clinical practice. Common variants, each with small effects, can accumulate into a score that shifts estimated risk upward or downward. For carriers of a pathogenic variant, this additional layer of information may change how clinicians think about surveillance intensity, timing of imaging, chemoprevention discussions, or prophylactic surgery counseling. The core issue is not whether hereditary risk exists — it does — but whether the inherited risk is uniform enough to justify the same management pathway for every carrier.
The abstract title signals a risk-stratification analysis rather than a therapeutic trial. Even without detailed endpoint data in the available record, the clinical intent is clear. Investigators are testing whether breast cancer risk can be reclassified once polygenic information is layered onto monogenic status. In practice, that means some carriers may move into higher-risk categories while others may land in a lower-risk band than expected from the pathogenic variant alone. A recalibration like this could influence who needs earlier MRI-based surveillance and who may be spared the assumption of uniformly extreme risk.
The biology behind this approach is plausible. Pathogenic variants in genes linked to hereditary breast cancer often confer substantial baseline risk, but penetrance is modified by the rest of the genome. Polygenic burden may nudge hormone signaling, DNA repair efficiency, cell-cycle control, or tumor microenvironment susceptibility in ways that are not visible when testing for a single gene defect. Genetic risk is therefore not a binary state; it is a layered architecture. A carrier with a favorable polygenic background may not behave like another carrier with the same pathogenic variant but a markedly less favorable polygenic profile.
In clinical terms, that distinction matters because risk counseling has to translate probability into action. When a woman is told she carries a pathogenic variant, the conversation often moves quickly toward heightened surveillance or preventive options. If a polygenic score refines that estimate, the counseling model becomes more individualized, and in some cases more defensible. The tradeoff is complexity: clinicians must explain why two people with the same monogenic result may no longer be managed identically. That creates pressure on genetics services, because risk communication has to be accurate, comprehensible, and emotionally workable.
A separate challenge is implementation. Polygenic scores depend on calibration, ancestry, and the population in which they were developed. Without careful validation, a score that performs well in one setting may misclassify risk in another. For hereditary breast cancer clinics, this is not an abstract methodological issue. It affects whether a patient is told she is at higher, average, or lower risk than expected, and those labels can change the trajectory of care for years. In a screening program, small shifts in estimated risk can have large downstream effects on MRI eligibility, referral patterns, and preventive surgery discussions.
The abstract also speaks to a broader transition in oncology genetics: moving from single-gene determinism to integrated risk modeling. Pathogenic variants remain highly important, but they may no longer be enough on their own to define risk categories with precision. A polygenic score is best understood as an added dimension, not a replacement for inherited cancer syndromes. For women carrying pathogenic variants, the practical question becomes whether that added dimension improves decision quality enough to justify routine use.
For now, the available material identifies the topic but not the study’s quantitative findings. No sample size, endpoint breakdown, or direction of reclassification is available in the scraped record, so any stronger claim would go beyond the evidence provided here. What the abstract does establish is the clinical direction of travel: breast cancer genetics is moving toward more granular stratification, and the combination of monogenic and polygenic information is increasingly being tested as a way to make hereditary risk assessment less blunt and more patient-specific.